Kornimate/medical-research-clean huggingface dataset:
a study of abt-652 in adults with osteoarthritis pain of the knee

Conditions: Osteoarthritis of the Knee

Summary: to compare the analgesic efficacy and safety of abt-652 administered twice daily (bid) to placebo in subjects with osteoarthritis (oa) of the knee.


Eligibility criteria:
inclusion criteria * history of oa of the knee joint and meeting american college of rheumatology (acr) clinical and radiographic criteria, * pain score as required by the protocol at screening and baseline * willing to washout of analgesics and to follow treatment plan, visit schedules and study procedures. exclusion criteria * history of sensitivity to histamine medications, acetaminophen (paracetamol), or non-steroidal anti-inflammatory drugs (nsaids) * active gastrointestinal (gi) disease, gi bleeding or gi ulceration, or history of gi bleeding or gi ulceration in the last 6 months * history of major psychiatric disorders * diagnosis of rheumatoid arthritis, autoimmune disorder, arthritis other than osteoarthritis involving the study joint, or other painful syndrome that could interfere with the assessment of pain at the study joint * any cardiac, respiratory, neurological or other medical condition or illness that is not well controlled with treatment
3d ultrasound of abdominal aortic aneurysm characteristics

Conditions: Abdominal Aortic Aneurysm

Summary: aaa characteristics are traditionally measured with computed tomography angiography (cta), however, three-dimensional ultrasound (3d us) is emerging as a novel imaging method for aaas. with the use of a us contrast agent, the aaa thrombus can also be distinguished from the lumen on the 3d scans. this enables 3d visualization of the aaa and its thrombus without the need for harmful radiation and nephrotoxic contrast agents, as opposed to cta. in in vitro measurements, 3d us has already been shown to have clinically acceptable error rate with aaa diameter and volume measurement. however, it is unclear whether this is also applicable to in vivo measurements. therefore, the aim of this prospective study is to compare preoperative 3d us aaa characteristics as measured by 3d us with contrast enhancement (3d ceus), 3d us without contrast enhancement (3d non-ceus) and cta.


Eligibility criteria:
inclusion criteria: * unruptured infrarenal or juxtarenal abdominal aortic aneurysm (aaa); * scheduled for elective endovascular repair (evar); * preoperative cta with iodine contrast available; * informed consent form understood and signed. exclusion criteria: * bmi\>40 kg/m2 * symptomatic aaa; * implanted pacemaker or icd; * unable to hold breath for ≤7 seconds; * pregnant; * hypersensitivity to the active substance(s) or any of the excipients in sonovue; * known right-to-left cardiac shunt; * severe pulmonary hypertension (pulmonary artery pressure \> 90mmhg); * uncontrolled systemic hypertension; * severe pulmonary disease (e.g. copd gold 3 or 4, adult respiratory distress syndrome); * clinically unstable cardiac disease (recent, \< 3 months, or ongoing myocardial infarction, unstable angina at rest, recent percutaneous coronary intervention, clinically worsening cardiac symptoms, severe cardiac arrhythmia's, endocarditis, etc.); * prosthetic valves; * loss of renal function (gfr \< 31 ml/min), end-stage renal disease; * end-stage liver disease; * sepsis; * hypercoagulable status, recent (\< 3 months) thrombosis; * congestive heart failure (class iii or iv); * psychiatric or other condition that may interfere with the study; * participating in another clinical study that interferes on the primary outcomes of this study; * 3d us measurement of aaa is impossible because of bowel gasses or other causes.
mood alterations in the patients with non-muscle invasive bladder cancer treated with bcg

Conditions: Non-Muscle Invasive Bladder Cancer

Summary: the purpose of this study is to evaluate mood changes in patients with non-muscle invasive bladder cancer who are receiving intravesical bacillus calmete-guerin (bcg). patients with non-muscle invasive bladder cancer receiving intravesical treatments are eligible to participate in this study. participation involves providing research blood and urine samples prior to the start of treatment and throughout the treatment course. the study team will also collect participant's medical history and clinical information. participants will be asked to complete questionnaires and daily mood diaries.

patients with non-muscle invasive bladder cancer who are receiving intravesical treatments are eligible to participate in this study. participants will be asked to complete the zung self-rating anxiety scale and zung self-rating depression scale prior to each induction intravesical treatment. during the 6-week induction intravesical treatment, participants will also be given a daily mood dairy to complete. urine specimens will be collected prior to each induction intravesical treatment and at each 3-month cystoscopy appointment during the treatment course. an at home urine collection may occur 6 hours post intravesical treatment. research blood samples will be collected prior to the first induction intravesical treatment, prior to the fourth intravesical treatment, and prior to each 3-month follow-up cystoscopy as indicated by the participant's treatment course. participants will be asked to complete the zung self-rating anxiety scale and zung self-rating depression scale prior to each 3-month follow-up cystoscopy during the treatment course. a 3-week daily mood diary will be completed by participants during the 3-week intravesical maintenance treatment. participants will be given a daily mood diary to complete between the 3-month follow-up cystoscopy appointments.

Eligibility criteria:
inclusion criteria: * subjects with a pathologically confirmed non-muscle invasive bladder cancer * age ≥ 18 years old * ability to understand and willingness to sign a written informed consent document exclusion criteria: * patients that are not candidates for intravesical treatment due to the nature of their disease, such as variant histology or progressive disease after a prior course of intravesical treatment. * patients who are pregnant

Keywords: bacillus calmette-guerin mood alterations
covid-19 and its effects on chronic pain patients

Conditions: Chronic Pain

Summary: pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. many factors can affect pain and its severity. this study aims to explore how the covid-19 affects chronic pain patients in terms of pain in general, intensity of pain, desire for pain treatment including follow up visits and pain medication refills as well as sleep.

research question what are the effects of the covid-19 on chronic pain patients in terms of pain and pain management? conceptual framework the covid-19 is a novel emerging infectious disease which has unimaginable and unbelievable large scale distressing effects worldwide. up to date, there is no study which aims to evaluate the effects of the covid-19 on chronic pain patients in terms of pain and pain management. the previous survey in patients focused on the worrisome of them for getting this infection and their confidence in their government to control the covid-19 situation in the us. materials and methods this study is an in-depth interview. the in-depth interview is the principal method to collect qualitative data by setting up open-ended questions beforehand. patients who are interviewed, can express their attitudes freely. this method is flexible which words, sentences and questions can be adjusted to suit each interviewee (participant). the process consists of active and intentional listening as well as ask on an in-depth basis. all conversations during the in-depth interview are tape-recorded.

Eligibility criteria:
inclusion criteria: * patients with chronic pain who have been under the health care service of the pain clinic of songklanagarind hospital. * chronic pain patients are patients with persistent pain for at least 3 months. pain can be from any etiologies. * the expected number of interviwees for this in-depth interview is 30 or until the gathered interview data are saturated. exclusion criteria: * patients who are not willing to participate this study and have time for an in person 'in-depth interview'. * patients who are not influence in thai language. * patients who are physically or mentally too ill to participate this study.
intensive drug therapy for ischemic stroke

Conditions: Ischemic Stroke

Summary: to observe the safety and efficacy of intensive drug therapy for ischemic stroke patients.patients with acute stroke caused by intracranial arterial stenosis (stenosis rate ≥70%) were enrolled and accept dual antiplatelet therapy (dapt) (aspirin 100 mg/d and clopidogrel 75 mg/d for 90 days, followed by aspirin 100 mg/d for long term) under the guidance of platelet function analysis (verifynow) combined with the intensive statin therapy (40 mg/d for 14 days, followed by 20 mg/d for long term).

patients (35 to 80 years ) with acute ischemic stroke, who can be treated within 72 hours of symptom onset will be enrolled. patients fulfilling all of the inclusion criteria and none of the exclusion criteria will be randomly selected.patients were treated with dual antiplatelet therapy (dapt) (aspirin 100 mg per day and clopidogrel 75 mg per day were administered for 90 days, followed by aspirin 100 mg per day for long term) and atorvastatin (40 mg per day for 14 days, followed by 20 mg per day long term) after enrollment. patients with aspirin resistance (aspirin reaction units \[aru\] ≥550) or clopidogrel resistance (p2y12 reaction units \[pru\] ≥208) were excluded on the 7th day of therapy.the primary objective is to observe the safety and efficacy of intensive drug therapy for ischemic stroke patients. a data and safety monitoring board (dsmb) will regularly monitor safety during the study. the trial has been approved by the ethics committee of huashan hospital.

Eligibility criteria:
inclusion criteria: * age between 35 and 80 years; * onset \<72 hours; * new-onset ischemic stroke confirmed by skull magnetic resonance diffusion weighted imaging (mr-dwi); * severe icas (stenosis ≥70%) indicated by time-of-flight magnetic resonance angiography (tof-mra). exclusion criteria: * ischemic stroke caused by other etiological factors (e.g., cardio-embolism, arterial dissection, vasculitis, etc.); * post-infarction hemorrhagic transformation and intraplaque hemorrhage as indicated by imaging examination; * contraindications to aspirin, clopidogrel, or atorvastatin; * intracranial hemorrhage within 3 months and a recent history of surgery or trauma; * severe organ impairment, liver insufficiency, and renal insufficiency; * complicated with tumors or hemorrhagic diseases; * use of drugs forbidden to use in combination after onset, including other antiplatelet drugs, anticoagulants, thrombolytic drugs, and drugs affecting antiplatelet agents and statin metabolism.
bone and muscle health following sleeve gastrectomy in men, premenopausal and postmenopausal women

Conditions: Bariatric Surgery; Bone Health; Severe Obesity; Muscle Health

Summary: background: bariatric surgery is gaining in popularity. while it's health benefits are undisputed, the older malabsorptive bariatric procedures (roux-in-y gastric bypass - rygb and biliopancreatic diversion - bpd) are associated with an increased risk of fractures and falls as early as 3-5 years after surgery. sleeve gastrectomy - sg is now the most performed bariatric procedure. although sg does not cause malabsorption, it is predicted to result in bone and muscle loss via weight loss and weight loss-independent mechanisms. primary aim: to compare the changes in spine volumetric bone mineral density (vbmd) by quantitative computed tomography (qct) and muscle mass at mid-femur by computed tomography (ct) at 3 years in the 3 groups of: 1) men; 2) premenopausal women; 3) postmenopausal women after sg versus their respective non-surgical peers who did not undergo sg in the 3-year period following recruitment. secondary aims: to compare the changes in vbmd by qct at skeletal sites other than the spine and in areal bone mineral density (abmd) by dual-energy x-ray absorptiometry (dxa), whole-body muscle mass by dxa, muscle quality by ct at mid-femur and muscle strength as well as in selected physical performance and capacity tests shown to predict falls and fractures between 0-1 and 1-3 years after sg in the same 3 groups after sg vs. in the respective non-surgical groups.


Eligibility criteria:
inclusion criteria: * men and women aged \>18 years; * awaiting sg for the bariatric group or meeting the criteria for sg but not undergoing surgery for the non-surgical group. * menopause: defined as the absence of menses for a year and a serum follicular-stimulating hormone (fsh) \>40 ui/l. * women taking oral contraceptive pills or hormone replacement therapy * patients with type 2 diabetes. exclusion criteria: * type 1 diabetes; * disease (e.g., uncontrolled thyroid disease, malabsorptive or overt inflammatory disorder) * metabolic bone disease other than osteoporosis or type 2 diabetes, * creatinine clearance \<30 ml/min) or medication (e.g., glucocorticoids, anti-epileptic drugs, osteoporosis therapy, thiazolidinediones) affecting bone metabolism; * weight \>204 kg (dxa weight limit) or bmi \>60 kg/m2 (upper limit to allow for qct examination); * current or planned pregnancy during follow-up; breast-feeding.

Keywords: bariatric surgery bone health severe obesity muscle health
p2y12 inhibitors utilization in bifurcation and chronic total occlusion pci

Conditions: Coronary Arteriosclerosis

Summary: prasugrel and ticagrelor were both associated with a significant reduction in the risk of mace in patients undergoing pci for an acs, mostly through a reduced stent thrombosis. the 1-year relative risk reduction (rrr) of definite of probable stent thrombosis in patients receiving a des were fairly different in triton-timi 38 and plato trials. the incidence of "biologically active" stent (des or bvs) thrombosis is largely variable according to different lesion settings. we aim to verify the translation of the postulated different reduction in thrombosis rate among various p2y12 inhibitors (clopidogrel, prasugrel and ticagrelor) in a high-risk setting such as the pci with des or bvs in cto and bifurcating lesions.

all patients aged 18-80 who underwent pci of a cto or bifurcating lesion (all medina types, side branch ≥2 mm) with "biologically active stents" (des or bvs) between january 2012 and december 2014 at participating centers will be deemed eligible to enter the registry. in-hospital outcomes will be recorded; all patients discharged alive will be followed up with a telephone interview (minimum follow-up 6 months). the primary end-point will be the occurrence of a cluster of major adverse cardiovascular events at 1 year: 1. death from any cause. 2. myocardial infarction. 3. stent thrombosis, defined as definite, probable or possible following the academic research consortium. sample size 3150 patients.

Eligibility criteria:
inclusion criteria: * age between 18-80 years old * pci of a cto or bifurcating lesion (all medina types, side branch ≥2 mm) with "biologically active stents" exclusion criteria: -none

Keywords: pci, cto, bifurcation, clopidogrel, prasugrel, ticagrelor
early detection of clinical deterioration in patients with covid-19 using machine learning

Conditions: Covid19

Summary: the aim of this study is to use artificial intelligence in the form of machine learning analysing vital signs as well as symptoms of patients suffering from covid19 to identify predictors of disease progression and severe course of disease.


Eligibility criteria:
inclusion criteria: * written informed consent * age \>= 18 years * detection of sars-cov2 within the past 5 days exclusion criteria: * inability to measure vital parameters and document symptoms

Keywords: machine learning artificial intelligence clinical course
role of steroids and extended scorpion anti-venom use in cardiac affection among scorpion stung pediatric cases

Conditions: Scorpion Envenomation

Summary: scorpion envenomation is considered a serious public health issue in the middle east and northern sahara . according to the world health organization (who), around 1.2 to 1.5 million individuals are suspected to scorpion stings annually in middle east; with 3000 to 5000 deaths rate .

in egypt, the percent of scorpion cases was 1.6% of all patients presented to ain shams university poison control center during 2019.initially within 1-2 hours of sting hypotension and bradycardia are encountered followed by hypotension and tachycardia between 4 and 48 hours due to severe left ventricular dysfunction and hypotension alone with good volume pulse and warm extremities is observed later in the recovery stage. cardiopulmonary problems such pulmonary edema and/or cardiogenic shock are the key characteristics of severe cases.myocardial ischemia, release of catechol amines, and the direct impact of scorpion venom on cardiac fibers are the main three explanations to these cardiac complications. inflammation is one of the key processes involved in the pathogenesis. neurotoxins can cause the release of inflammatory mediators. increased pulmonary vascular permeability following the release of inflammatory mediators, such as platelet activating factor, leukotrienes, and prostaglandins had been suggested to explain the development of cardiogenic pulmonary edema. troponin is the biomarker of choice for the detection of cardiac injury. cardiac troponin i (ctni) isoform is predominant in myocardial tissue .increased serum levels of pro-inflammatory cytokines, interleukins and tumor necrosis factor alpha had also been observed in many experimental studies following scorpion envenomation in plasma and in rat lungs respectively and on humans. scorpion anti-venom has a significant role in life saving of stung patients, but there is still a conflict about the duration of its administration mainly after occurrence of myocardial toxicity in stung patients. corticosteroids are known to decrease the level of inflammatory mediators produced during the process of inflammation including cytokines. dexamethasone is steroid with powerful anti-inflammatory effect that works by calming down body's immune response to reduce pain, itching and swelling .

Eligibility criteria:
inclusion criteria: - patients with scorpion stings and diagnosed as grade 1, 2 \& 3 (according to recent history of scorpion sting and clinical presentation at the time of admission) . exclusion criteria: * patients with history of cardiac disease, or previous cardiac operation and or previous abnormal cardiac investigations . * patients with history of chronic renal, hepatic, chest or cns diseases . * patients with chronic inflammatory diseases such as auto-immune diseases, with chronic use of corticosteroids . * envenomated cases that are described as grade 4 scorpion envenomation. * cases of scorpion sting above age of 18 years.
effect of fish oil and vitamin c on exercise-induced bronchoconstriction and airway inflammation in asthma

Conditions: Asthma

Summary: combining fish oil and vitamin c supplementation will provide a greater anti-inflammatory effect against developing exercise-induced bronchoconstriction (eib) than either nutritional supplement alone.

the aim of this study is to extend previous findings that nutritional supplementation or dietary modification can ameliorate exercise-induced bronchoconstriction. it has been shown in separate studies that fish oil and ascorbic acid (vitamin c) individually protect against eib by improving pulmonary function and reducing airway inflammation. the main aim of this study is to determine the comparative and additive effects of fish oil and ascorbic acid supplementation on eib and airway inflammation in asthmatic individuals.

Eligibility criteria:
inclusion criteria: * diagnosis of asthma, based on medication use as well as history and symptoms as outlined in the nhlbi guidelines for the diagnosis and management of asthma * diagnosis of eib, based on ≥10% fall in post-challenge fev1, a measure of lung function, after dry air eucapnic voluntary hyperventilation (evh), a simulated exercise challenge * not currently taking asthma maintenance medication or physician approval to discontinue current asthma medication for the duration of the study * not currently taking any fish oil or ascorbic acid supplements above the level recommended for adequate intake (if currently taking supplements, can participate if the subject stops taking the supplements for 2 weeks before starting the study and throughout the study) * agree to limit fish consumption to 1 fish meal per week throughout the study * agree to avoid vitamin c-rich foods throughout the study exclusion criteria: * resting fev1 (the amount of air blown out in the first second of a forced exhalation) \<60% of predicted when off medication * pregnancy * history of cardiovascular disease, including hyperlipidemia (high cholesterol) and hypertension (high blood pressure) * history of bleeding disorders or delayed clotting time * history of diabetes * history of seizures * allergy to fish oil or ascorbic acid (vitamin c)

Keywords: asthma exercise-induced bronchoconstriction inflammation airway fish oil ascorbic acid
iron deficiency in acute myocardial infarction: prevalence pilot study

Conditions: Acute Myocardial Infarction

Summary: acute myocardial infarction (heart attacks) affect about 86000 people each year in the uk. given this large number of people, it is important that health teams look at ways to ensure the best care to improve outcomes after a heart attack. in related heart conditions, the role of iron is important, but there isn't much information about what effect iron levels have on patients following a heart attack. we want to plan a large scale study to look at this, but need some early data to understand how many patients have low iron levels. this small study will take part at one nhs trust and will test for iron levels in all patients who provide consent (we expect up to 70 patients will take part). we will also collect data from medical notes for these patients and use all of this information together to understand more about iron and to plan a larger study.


Eligibility criteria:
inclusion: 1. - adults patients who sign an informed consent form. 2. - type 1 myocardial infarction within the previous 10 days exclusion 1 - not fulfilling inclusion criteria
wireless assessment of respiratory and circulatory distress in chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease; Dyspnea

Summary: for patients admitted to the medical ward, it is usually difficult to predict if their clinical condition will deteriorate, however subtle changes in vital signs are usually present 8 to 24 hours before a life-threatening event such as respiratory failure leading to icu admission, or unanticipated cardiac arrest. such adverse trends in clinical observations can be missed, misinterpreted or not appreciated as urgent. new continuous and wearable 24/7 clinical vital parameter monitoring systems offer a unique possibility to identify clinical deterioration before patients progress beyond the point-of-no-return, where adverse events are inevitable. the ward-copd project aims to determine the number and duration of cardiopulmonary micro events during the first 4 days after hospital admission with acute exacerbation of copd. we will also test the server installation, develop a database of core data and assess the frequency of artefacts and failure to capture the continuous monitoring signal.


Eligibility criteria:
inclusion criteria: adult patients admitted to hospital for acute exacerbation of copd (aecopd). investigators will review the electronic patient chart for a primary diagnosis of aecopd. exclusion criteria: * patient expected not to cooperate. * patient allergic to plaster, plastic or silicone. * active therapy withdrawn

Keywords: wireless monitoring continuous monitoring vital parameters clinical deterioration